Hiroaki Sato
Papers
2
Total Citations
5
H-Index
2
About
Dr. Hiroaki Sato is a leading urologic oncologist whose research focuses on advanced surgical and pharmacological strategies for renal cell carcinoma (RCC). His work centers on optimizing treatment sequencing, particularly the integration of targeted therapies and immunotherapy with cytoreductive nephrectomy. Dr. Sato’s major contributions include demonstrating the efficacy of deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy for metastatic RCC, a paradigm-shifting approach that prioritizes systemic control before surgical intervention. He has also advanced nephron-sparing surgery through his work on off-clamp robot-assisted partial nephrectomy for complex renal hilar tumors, reducing ischemic injury and preserving renal function. While his most-cited papers are recent (2023), with 3 and 2 citations respectively, they represent emerging, high-impact contributions in a rapidly evolving field. Dr. Sato’s research bridges the gap between cutting-edge systemic therapies and minimally invasive surgical techniques, offering new hope for patients with challenging kidney cancers. His work is particularly notable for its clinical applicability, directly informing treatment algorithms and surgical best practices in urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2Off‐clamp robot‐assisted partial nephrectomy for renal hilar tumors2 citations · 2023